Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease Journal Article

  

Authors:	Przepiorka, D.; Kernan, N. A.; Ippoliti, C.; Papadopoulos, E. B.; Giralt, S.; Khouri, I.; Lu, J. G.; Gajewski, J.; Durett, A.; Cleary, K.; Champlin, R.; Andersson, B. S.; Light, S.
Article Title:	Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease
Abstract:	Daclizumab, a humanized monoclonal IgG1 directed against the a chain of the interleukin-2 receptor (IL-2R), is a competitive inhibitor of IL-2 on activated lymphocytes, To test the hypothesis that specific inhibition of activated lymphocytes in patients with ongoing acute graft-versus-host disease (GVHD) might ameliorate the process, we treated 43 patients with advanced or steroid-refractory GVHD with daclizumab. The first cohort of 24 patients was treated with daclizumab 1 mg/kg on days 1, 8, 15, 22, and 29, On day 43, the complete response (CR) rate was 29% (95% confidence interval [CI], 13%-51%), Survival on day 120 was 29% (95% CI, 13%-51%), A second cohort of 19 patients was treated with daclizumab 1 mg/kg on days 1, 4, 8, 15, and 22, For these patients, the CR rate on day 43 was 47% (95% CI, 24%-71%), and survival on day 120 was 53% (95% CI, 29%-76%), There were no infusion-related reactions and no serious side effects related to daclizumab, Following treatment, there was a reduction in serum concentrations of soluble IL-2R and peripheral blood CD3(+)25(+) lymphocytes, but these changes were not predictive of response. Daclizumab has substantial activity for the treatment of acute GVHD, and the second regimen evaluated is recommended for a controlled study. (C) 2000 by The American Society of Hematology.
Keywords:	analysis; prophylaxis; monoclonal-antibody; immunotoxin; bone-marrow transplantation; alloreactive t-cells; retrospective; renal-transplantation; il-2 receptor; soluble interleukin-2 receptor; tac antibody
Journal Title:	Blood
Volume:	95
Issue:	1
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2000-01-01
Start Page:	83
End Page:	89
Language:	English
ACCESSION:	WOS:000084538600013
PROVIDER:	wos
PUBMED:	10607689
DOI:	10.1182/blood.V95.1.83
Notes:	Article -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/86533